Bücher: „Rheumatoid arthritis Immunological aspects“

1

Radboud J. E. M. Dolhain. T cells in the inflamed joints of patients with rheumatoid arthritis. [Leiden: University of Leiden, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

David, Isenberg, und Rademacher T. W, Hrsg. Abnormalities of IgG glycosylation and immunological disorders. Chichester: Wiley, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

S, Panayi Gabriel, Hrsg. Immunology of the connective tissue diseases. Dordrecht: Kluwer Academic Publishers, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

M, Cutolo, und New York Academy of Sciences., Hrsg. Basic and clinical aspects of neuroendocrine immunology in rheumatic diseases. Boston, Mass: Blackwell Pub. on behalf of the New York Academy of Sciences, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

H, Phillips Robert. Coping with rheumatoid arthritis. Garden City Park, N.Y: Avery Pub. Group, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Pritchard, Mary L. Psychological aspects of rheumatoid arthritis. New York: Springer-Verlag, 1989.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Pritchard, Mary L. Psychological Aspects of Rheumatoid Arthritis. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4613-9666-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Leitch, Michael. Living with arthritis: People with arthritis talk about coping from day to day. Bath: Chivers, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

C, Singleton Mary, und Branch Eleanor F, Hrsg. Physical therapy and the arthritis patient: Clinical aspects and approaches to management. New York: Haworth Press, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Ronday, H. K. Aspects of proteolytic joint destruction in rheumatoid arthritis. Leiden: University of Leiden, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Rona, Zoltan P. Rheumatoid arthritis: Decrease or reverse symptoms-naturally. Vancouver: Alive Books, 2000.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Rona, Zoltan P. Rheumatoid arthritis: Decrease or reverse symptoms-- naturally. Summertown, Tenn: Alive books, 2007.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Mäkeläinen, Paula. Rheumatoid arthritis patient education and self-efficacy. Kuopio: Kuopion Yliopisto, 2009.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Mäkeläinen, Paula. Rheumatoid arthritis patient education and self-efficacy. Kuopio: Kuopion Yliopisto, 2009.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Taal, Erik. Self-efficacy, self-management, and patient education in rheumatoid arthritis. Delft, the Netherlands: Eburon, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Nordenskiöld, Ulla. Daily activities in women with rheumatoid arthritis: Aspects of patient education, assistive devices and methods for disability and impairment assessment. Oslo: Scandinavian University Press, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Zierhut, Manfred. Immunology of the joint and the eye. Boston: Butterworth-Heinemann, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Poehlmann, Katherine M. Rheumatoid arthritis: The infection connection : targeting and treating the cause of chronic illness. Rolling Hills Estates, CA: Satori Press, 2002.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Nelsen, Laura. Free from pain of rheumatoid arthritis: Without drugs, exercise, or diet : new safe, simple, do-it-yourself methods anyone can use. Phoenix, Ariz: Sundance Pub. Co., 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Hayes, Diana L. Trouble don't last always: Soul prayers. Collegeville, Minn: Liturgical Press, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

1953-, López-Larrea Carlos, Hrsg. HLA-B27 in the development of spondyloarthropathies. New York: Springer, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

1954-, Kresina Thomas F., Hrsg. Monoclonal antibodies, cytokines, and arthritis: Mediators of inflammation and therapy. New York: M. Dekker, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Lahita, Robert, J. W. J. Bijlsma, Alfonse Masi und Rainer Straub. Basic and Clinical Aspects of Neuroendocrine Immunology in Rheumatic Diseases (Annals of the New York Academy of Sciences). Blackwell Publishing Limited, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Pritchard, Mary L. Psychological Aspects of Rheumatoid Arthritis. Springer, 2011.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Shirazi, Aida. Nutrient intake of women with rheumatoid arthritis before and after receiving arthritis medication. 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Scott, David L., James Galloway, Andrew Cope, Arthur Pratt und Vibeke Strand, Hrsg. Oxford Textbook of Rheumatoid Arthritis. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.001.0001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

This new textbook provides a comprehensive overview of the scientific and clinical aspects of rheumatoid arthritis (RA). Split into eight sections—history, diagnosis, and epidemiology; pathogenesis; clinical presentation; disease assessment; impact on life; non-drug treatments; drug treatments; and management and outcomes—it collects the contemporary ideas about RA and explains the revolutionary changes that have taken place over the past two decades, and indicates areas of future research. Witten by leading clinicians and scientists in the field, each chapter gives a detailed background, key recent advances, areas of doubt, and future directions of research.

27

1955-, Miossec Pierre, Berg, Wim B. van den, 1950- und Firestein Gary S, Hrsg. T cells in arthritis. Basel: Birkhauser Verlag, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Pilkington, Clarissa. Juvenile idiopathic arthritis: medical aspects. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199550647.003.013002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

♦ Juvenile idiopathic arthritis is defined as an arthritis persisting for at least 6 weeks♦ The cause may relate to the immune system response to a stimulus with a synovial or systemic manifestation♦ Classification depends on the clinical picture and the immunological markers♦ Joint sepsis is often a differential diagnosis♦ Most cases respond to simple measures, a few need a structured medical management plan. Surgery is indicated in 10% of cases. All require physiotherapy♦ Complications may occur secondary to the disease or its treatment.

29

Strahl, Carolyn Jane. The role of pain anxiety, coping strategies, and self-efficacy in rheumatoid arthritis patient funtioning. 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Scarpa, Raffaele, Francesco Caso, Luisa Costa, Rosario Peluso, Nicola Matteo Dario Di Minno und Antonio Del Puente. Peripheral arthritis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Clinical presentation of peripheral arthritis in patients with psoriatic arthritis (PsA), has been described by Moll and Wright who classified it into four subsets: symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis and arthritis mutilans. In the symmetrical polyarthritis subset, the distribution of articular involvement is similar to rheumatoid arthritis and this has for many years justified the inappropriate use of the terminology ‘rheumatoid-like form’, at present completely abandoned. Oligoarthritis is characterized by asymmetrical involvement of few joints (less than four), which include scattered DIP or proximal interphalangeal (PIP) joints and/or metatarsophalangeal joints. DIP arthritis may occur with symmetrical or asymmetrical features, and it is often in strict association with onycopathy. The arthritis mutilans pattern is characterized by osteolysis of phalanx and metacarpals and it is very rare, occurring in less than 1% of patients with established form of arthritis. In 15-20% of the cases the arthritis may precede the onset of the psoriatic skin rash. Consequently, psoriatic arthritis ‘sine psoriasis’ should not be considered a rare clinical finding. In this subset articular involvement is clinically expressed, while cutaneous is apparently absent. Laboratory tests and imaging are relevant for differential diagnosis which in some presentations may represent a diagnostic challenge. The outcome of peripheral patterns of PsA patients is related not only to the spectrum of peripheral phenotypes, but also to early diagnosis, and metabolic aspects, which may affect excess in morbidity and mortality.

31

Avery, Andrea. Sonata: A Memoir of Pain and the Piano. Norton & Company, Incorporated, W. W., 2018.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Avery, Andrea. Sonata: A memoir of pain and the piano. 2017.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Avery, Andrea. Sonata. Pegasus Books, 2017.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Witte, Maria-Brigitta. Koharenzgefuhl Und Krankheits-verarbeitung Bei Patientinnen Und Patienten Mit Chronischer Polyarthritis (Europaische Hochschulschriften: Reihe). Peter Lang Publishing, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

J, Carlson-Newberry Sydne, Southern California Evidence-Based Practice Center/RAND. und United States. Agency for Healthcare Research and Quality., Hrsg. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Lopez-Larrea, Carlos. Hla-B27 in the Development of Spondyloarthropathies. R G Landes Co, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Malaviya, Anand, und Ashok Kumar. Axial spondyloarthritis in India. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198734444.003.0030.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Spondyloarthritis (SpA) is among the commonest rheumatological conditions in India, second only to rheumatoid arthritis (RA). This is consistent with the fact that the prevalence of SpA is linked to the prevalence of HLA-B27 in that population. Its prevalence in different regions of the country has been reported to be approximately 6%. That would put India prominently on the SpA map of the world, reflected in the large number of publications from the late 1970s onwards, dispelling any earlier misconceptions that it is largely a ‘white man’s disease’. This chapter summarizes the various aspects of SpA as reported from India.

38

Strand, Vibeke, Jeremy Sokolove und Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0030.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, 'first-in-human' to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

39

Strand, Vibeke, Jeremy Sokolove und Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

40

Strand, Vibeke, Jeremy Sokolove und Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

41

Price, Elizabeth J., und Anwar R. Tappuni, Hrsg. Oxford Textbook of Sjögren's Syndrome. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198806684.001.0001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

The Oxford Textbook of Sjögren’s Syndrome is an authoritative textbook, rich with valuable illustrations and figures, providing a practical guide to diagnosing and managing all aspects of this condition. Sjögren’s syndrome is a chronic, immune-mediated condition typically presenting in women in their fifth or sixth decade. With increased awareness and improvement in diagnostic tests, younger women and occasionally men are now being diagnosed with this condition. Frequently, Sjögren’s syndrome occurs in association with other autoimmune diseases, usually rheumatoid arthritis, systemic lupus erythematosus, or scleroderma. The hallmark of this condition is dryness of the eyes and mouth, but many patients have systemic effects that can be debilitating, including fatigue, peripheral neuropathy, and lung damage. It has potentially serious long-term complications, including a higher risk of developing lymphoma and foetal congenital heart block. Diagnosis of the condition can be challenging as the presenting symptoms are variable. Management of the condition can be complex as the course of the disease is unpredictable and the available therapy is mainly symptomatic, with no known cure as yet. Experts in the condition from around the world have contributed to this book to provide the most up-to-date information on pathophysiology, classification criteria, diagnostic tests, systemic manifestations of the disease, and emerging therapeutic options. The publication of this book coincides with a period of increased interest in Sjögren’s within the scientific, medical, and pharmacological worlds.

Bücher zum Thema „Rheumatoid arthritis Immunological aspects“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an